BANK VONTOBEL/CALL/BIOGEN IDEC/280/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 11:21:51 17/05/2024 pm IST | ||
| 0.87 EUR | -4.40% |
|
| Current month | +54.24% | ||
| 1 month | +102.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.87 | -4.40% |
| 16/24/16 | 0.91 | -18.02% |
| 15/24/15 | 1.11 | +40.51% |
| 14/24/14 | 0.79 | -3.66% |
| 13/24/13 | 0.82 | +12.33% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 11:21 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM7SCT |
| ISIN | DE000VM7SCT1 |
| Date issued | 02/01/2024 |
| Strike | 280 $ |
| Maturity | 20/12/2024 (217 Days) |
| Parity | 10 : 1 |
| Emission price | 2.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.61 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.03 € |
| Spread % | 3.16% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Warrants
- Warrant